A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

"Some patients also receive chemotherapy, but the data are mixed on its effectiveness and it's also very toxic, so we were interested in seeing whether immunotherapy could improve outcomes for ...

Findings, demonstrated by the phase 2 PERLA trial, were presented at the 2024 Society for Immunotherapy of Cancer (SITC) ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...

Glioblastoma is the most common and deadliest form of brain cancer. Patients face a bleak prognosis—the average survival ...

Research reveals SLC13A3's role in tumor cell survival and immune therapy resistance, highlighting its potential as a target ...

Encouraging Preclinical Data: Decoy20 has produced efficacy in preclinical studies across a variety of tumor types and in combination with four different classes of existing drugs, demonstrating both ...

Associate professor Satoshi Watanabe and his teams from Niigata University have revealed that PET/CT image analysis using ...

In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the results from the phase 3 KEYNOTE-522 trial.

An immunotherapy approach to treating advanced ... to receive the antibody drug brentuximab vedotin along with the chemotherapy drugs doxorubicin, vinblastine and dacarbazine, while 498 others ...